Human CMV-specific T-cell responses in kidney transplantation; Toward changing current risk-stratification paradigm

Transplant International

Volumn 27, Issue 7, 2014, Pages 643-656

  Lúcia, Marc ^a   Crespo, Elena ^a   Cruzado, Josep M ^a,b   Grinyõ, Josep M ^a,b   Bestard, Oriol ^a,b  

^a BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

human cytomegalovirus; immune monitoring; immunosuppression; kidney transplantation; T cell immune response

Indexed keywords

ALEMTUZUMAB; CALCINEURIN INHIBITOR; CYCLOSPORIN A; EVEROLIMUS; GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; RAPAMYCIN; THYMOCYTE ANTIBODY;

ADAPTIVE IMMUNITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL PRACTICE; CYTOMEGALOVIRUS INFECTION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; HUMAN CYTOMEGALOVIRUS; HUMORAL IMMUNITY; IMMUNOBIOLOGY; IMMUNOCOMPETENCE; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGICAL MONITORING; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; INNATE IMMUNITY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MEDICAL DECISION MAKING; PERSONALIZED MEDICINE; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; RELIABILITY; REVIEW; RISK MANAGEMENT; STANDARDIZATION; SURGICAL RISK; VIRUS IMMUNITY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; HISTOCOMPATIBILITY; IMMUNOLOGY; RISK; T LYMPHOCYTE;

CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; ENZYME-LINKED IMMUNOSPOT ASSAY; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; RISK; T-LYMPHOCYTES; TRANSPLANTATION IMMUNOLOGY;

EID: 84902547672     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12318     Document Type: Review

References (97)

1. Sagedal S, Nordal KP, Hartmann A, et al,. The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am J Transplant 2002; 2: 850.
2. Sagedal S, Hartmann A, Nordal KP, et al,. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int 2004; 66: 329.
3. Hjelmesaeth J, Sagedal S, Hartmann A, et al,. Asymptomatic cytomegalovirus infection is associated with increased risk of new-onset diabetes mellitus and impaired insulin release after renal transplantation. Diabetologia 2004; 47: 1550.
4. Hodson EM, Jones CA, Webster AC, et al,. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet 2005; 365: 2105.
5. Einsele H, Ehninger G, Steidle M, et al,. Lymphocytopenia as an unfavorable prognostic factor in patients with cytomegalovirus infection after bone marrow transplantation. Blood 1993; 82: 1672.
6. Einsele H, Hebart H,. Cytomegalovirus infection following stem cell transplantation. Haematologica 1999; 84 (Suppl. E): 46.
7. Blyth E, Clancy L, Simms R, et al,. Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation. Blood 2013; 121: 3745.
8. Brestrich G, Zwinger S, Fischer A, et al,. Adoptive T-cell therapy of a lung transplanted patient with severe CMV disease and resistance to antiviral therapy. Am J Transplant 2009; 9: 1679.
9. Munksgaard B,. Cytomegalovirus. Am J Transplant 2004; 4 (Suppl. 10): 51.
10. Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG,. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005; 143: 870.
11. Kotton CN, Kumar D, Caliendo AM, et al,. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010; 89: 779.
12. Preiksaitis JK, Brennan DC, Fishman J, Allen U,. Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant 2005; 5: 218.
13. Kliem V, Fricke L, Wollbrink T, Burg M, Radermacher J, Rohde F,. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am J Transplant 2008; 8: 975.
14. Witzke O, Hauser IA, Bartels M, Wolf G, Wolters H, Nitschke M,. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial. Transplantation 2012; 93: 61.
15. Luan FL, Stuckey LJ, Park JM, et al,. Six-month prophylaxis is cost effective in transplant patients at high risk for cytomegalovirus infection. J Am Soc Nephrol 2009; 20: 2449.
16. Blumberg EA, Hauser IA, Stanisic S, et al,. Prolonged prophylaxis with valganciclovir is cost effective in reducing posttransplant cytomegalovirus disease within the United States. Transplantation 2010; 90: 1420.
17. Couzi L, Helou S, Bachelet T, et al,. High incidence of anticytomegalovirus drug resistance among D+R- kidney transplant recipients receiving preemptive therapy. Am J Transplant 2012; 12: 202.
18. Khoury JA, Storch GA, Bohl DL, et al,. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 2006; 6: 2134.
19. Reischig T, Jindra P, Hes O, Svecová M, Klaboch J, Treska V,. Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. Am J Transplant 2008; 8: 69.
20. Singh N,. Antiviral drugs for cytomegalovirus in transplant recipients: advantages of preemptive therapy. Rev Med Virol 2006; 16: 281.
21. Grundy JE, Lui SF, Super M, et al,. Symptomatic cytomegalovirus infection in seropositive kidney recipients: reinfection with donor virus rather than reactivation of recipient virus. Lancet 1988; 2: 132.
22. + T-cell immunity. Am J Transplant 2008; 8: 1749.
23. Atabani SF, Smith C, Atkinson C, et al,. Cytomegalovirus replication kinetics in solid organ transplant recipients managed by preemptive therapy. Am J Transplant 2012; 12: 2457.
24. Emery VC, Asher K, Sanjuan Cde J,. Importance of the cytomegalovirus seropositive recipient as a contributor to disease burden after solid organ transplantation. J Clin Virol 2012; 54: 125.
25. Humar A, Lebranchu Y, Vincenti F, et al,. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010; 10: 1228.
26. Boehme KW, Compton T,. Innate sensing of viruses by toll-like receptors. J Virol 2004; 78: 7867.
27. Compton T, Kurt-Jones EA, Boehme KW, et al,. Human cytomegalovirus activates inflammatory cytokine responses via CD14 and Toll-like receptor 2. J Virol 2003; 77: 4588.
28. Kijpittayarit S, Eid AJ, Brown RA, Paya CV, Razonable RR,. Relationship between Toll-like receptor 2 polymorphism and cytomegalovirus disease after liver transplantation. Clin Infect Dis 2007; 44: 1315.
29. Mezger M, Steffens M, Semmler C, et al,. Investigation of promoter variations in dendritic cell-specific ICAM3-grabbing non-integrin (DC-SIGN) (CD209) and their relevance for human cytomegalovirus reactivation and disease after allogeneic stem-cell transplantation. Clin Microbiol Infect 2008; 14: 228.
30. Manuel O, Pascual M, Trendelenburg M, Meylan PR,. Association between mannose-binding lectin deficiency and cytomegalovirus infection after kidney transplantation. Transplantation 2007; 83: 359.
31. Bukowski JF, Woda BA, Habu S, Okumura K, Welsh RM,. Natural killer cell depletion enhances virus synthesis and virus-induced hepatitis in vivo. J Immunol 1983; 131: 1531.
32. Polic̈ B, Hengel H, Krmpotic̈ A, et al,. Hierarchical and redundant lymphocyte subset control precludes cytomegalovirus replication during latent infection. J Exp Med 1998; 188: 1047.
33. Venema H, van den Berg AP, van Zanten C, van Son WJ, van der Giessen M, The TH,. Natural killer cell responses in renal transplant patients with cytomegalovirus infection. J Med Virol 1994; 42: 188.
34. Hadaya K, de Rham C, Bandelier C, et al,. Natural killer cell receptor repertoire and their ligands, and the risk of CMV infection after kidney transplantation. Am J Transplant 2008; 8: 2674.
35. Stern M, Elsässer H, Hönger G, Steiger J, Schaub S, Hess C,. The number of activating KIR genes inversely correlates with the rate of CMV infection/reactivation in kidney transplant recipients. Am J Transplant 2008; 8: 1312.
36. Boppana SB, Britt WJ,. Antiviral antibody responses and intrauterine transmission after primary maternal cytomegalovirus infection. J Infect Dis 1995; 171: 1115.
37. Jonjic̈ S, Pavic̈ I, Polic̈ B, Crnkovic̈ I, Lucin P, Koszinowski UH,. Antibodies are not essential for the resolution of primary cytomegalovirus infection but limit dissemination of recurrent virus. J Exp Med 1994; 179: 1713.
38. Genini E, Percivalle E, Sarasini A, Revello MG, Baldanti F, Gerna G,. Serum antibody response to the gH/gL/pUL128-131 five-protein complex of human cytomegalovirus (HCMV) in primary and reactivated HCMV infections. J Clin Virol 2011; 52: 113.
39. Falagas ME, Snydman DR, Ruthazer R, et al,. Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group. Clin Transplant 1997; 11 (5 Pt 1): 432.
40. Humar A, Mazzulli T, Moussa G, et al,. Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R- transplant recipients. Am J Transplant 2005; 5: 1065.
41. + T lymphocytes. J Virol 1990; 64: 5457.
42. Shabir S, Kaul B, Pachnio A, et al,. Impaired direct priming of CD8 T cells by donor-derived cytomegalovirus following kidney transplantation. J Am Soc Nephrol 2013; 24: 1698.
43. Gamadia LE, Rentenaar RJ, van Lier RA, ten Berge IJ,. Properties of CD4(+) T cells in human cytomegalovirus infection. Hum Immunol 2004; 65: 486.
44. + T-cell clones specifically activated by IE1 peptides in vitro. J Virol 1996; 70: 2162.
45. Walter EA, Greenberg PD, Gilbert MJ, et al,. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995; 333: 1038.
46. Elkington R, Shoukry NH, Walker S, et al,. Cross-reactive recognition of human and primate cytomegalovirus sequences by human CD4 cytotoxic T lymphocytes specific for glycoprotein B and H. Eur J Immunol 2004; 34: 3216.
47. Hopkins JI, Fiander AN, Evans AS, Delchambre M, Gheysen D, Borysiewicz LK,. Cytotoxic T cell immunity to human cytomegalovirus glycoprotein. Br J Med Virol 1996; 49: 124.
48. + T lymphocytes with cellular maturation. J Exp Med 2006; 203: 2865.
49. Crough T, Burrows JM, Fazou C, Walker S, Davenport MP, Khanna R,. Contemporaneous fluctuations in T cell responses to persistent herpes virus infections. Eur J Immunol 2005; 35: 139.
50. Gillespie GM, Wills MR, Appay V, et al,. Functional heterogeneity and high frequencies of cytomegalovirus-specific CD8(+) T lymphocytes in healthy seropositive donors. J Virol 2000; 74: 8140.
51. +-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers. J Virol 2003; 77: 5226.
52. + cytotoxic T-cell response in natural infection. Blood 2004; 104: 1075.
53. + T cells dominate the memory compartments of exposed subjects. J Exp Med 2005; 202: 673.
54. Pahl-Seibert M-F, Juelch M, Podlech J, et al,. Highly protective in vivo function of cytomegalovirus IE1 epitope-specific memory CD8 T cells purified by T-cell receptor-based cell sorting. J Virol 2005; 79: 5400.
55. Bunde T, Kirchner A, Hoffmeister B, et al,. Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J Exp Med 2005; 201: 1031.
56. Nickel P, Bold G, Presber F, et al,. High levels of CMV-IE-1-specific memory T cells are associated with less alloimmunity and improved renal allograft function. Transpl Immunol Elsevier BV 2009; 20: 238.
57. + T cells comprise both naive and memory cells. J Immunol 1999; 162: 7080.
58. Stinski MF,. Sequence of protein synthesis in cells infected by human cytomegalovirus: early and late virus-induced polypeptides. J Virol 1978; 26: 686.
59. Rice GP, Schrier RD, Oldstone MB,. Cytomegalovirus infects human lymphocytes and monocytes: virus expression is restricted to immediate-early gene products. Proc Natl Acad Sci USA 1984; 81: 6134.
60. Waldman WJ, Knight DA, Huang EH, Sedmak DD,. Bidirectional transmission of infectious cytomegalovirus between monocytes and vascular endothelial cells: an in vitro model. J Infect Dis 1995; 171: 263.
61. Egli A, Humar A, Kumar D,. State-of-the-art monitoring of cytomegalovirus-specific cell-mediated immunity after organ transplant: a primer for the clinician. Clin Infect Dis 2012; 55: 1678.
62. Best NG, Trull AK, Tan KK, Spiegelhalter DJ, Wreghitt TG, Wallwork J,. Blood cyclosporine concentrations and cytomegalovirus infection following heart transplantation. Transplantation 1995; 60: 689.
63. Razonable RR,. Strategies for managing cytomegalovirus in transplant recipients. Expert Opin Pharmacother 2010; 11: 1983.
64. Fietze E, Prosch S, Reinke P, et al,. Cytomegalovirus infection in transplant recipients. The role of tumor necrosis factor. Transplantation 1994; 58: 675.
65. San Juan R, Aguado JM, Lumbreras C, et al,.; RESITRA Network of the Spanish Study Group of Infection in Transplantation. Impact of current transplantation management on the development of cytomegalovirus disease after renal transplantation. Clin Infect Dis 2008; 47: 875.
66. Ekberg H, Bernasconi C, Noldeke J, et al,. Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the Symphony study. Nephrol Dial Transplant 2010; 25: 2004.
67. Brennan DC, Legendre C, Patel D, et al,. Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: pooled analysis of three clinical trials. Am J Transplant 2011; 11: 2453.
68. Moorman NJ, Shenk T,. Rapamycin-resistant mTORC1 kinase activity is required for herpesvirus replication. J Virol 2010; 84: 5260.
69. Thoreen CC, Kang SA, Chang JW, et al,. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem 2009; 284: 8023.
70. Ferrer IR, Araki K, Ford ML,. Paradoxical aspects of rapamycin immunobiology in transplantation. Am J Transplant 2011; 11: 654.
71. Araki K, Turner AP, Shaffer VO, et al,. mTOR regulates memory CD8 T-cell differentiation. Nature 2009; 460: 108.
72. ™ interferon-γ releasing assays in assessing risk of CMV infection in kidney transplant recipients. J Clin Microbiol 2013; 51: 2501.
73. Bestard O, Crespo E, Stein M,. Cross-validation of IFN-g elispot assay for measuring alloreactive memory/effector T cell responses in renal transplant recipients. Am J Transplant 2013; 13: 1880.
74. Ashoor I, Najafian N, Korin Y, et al,. Standardization and cross validation of alloreactive IFNγ ELISPOT assays within the clinical trials in organ transplantation consortium. Am J Transplant 2013; 13: 1871.
75. Sester U, Gärtner BC, Wilkens H, et al,. Differences in CMV-specific T-cell levels and long-term susceptibility to CMV infection after kidney, heart and lung transplantation. Am J Transplant 2005; 5: 1483.
76. Sester M, Sester U, Gärtner B, et al,. Levels of virus-specific CD4 T cells correlate with cytomegalovirus control and predict virus-induced disease after renal transplantation. Transplantation 2001; 71: 1287.
77. Sund F, Lidehäll AK, Claesson K, et al,. CMV-specific T-cell immunity, viral load, and clinical outcome in seropositive renal transplant recipients: a pilot study. Clin Tranplant 2010; 24: 401.
78. Gerna G, Lilleri D, Fornara C, et al,. Monitoring of human cytomegalovirus-specific CD4+ and CD8+ T-Cell immunity in patients receiving solid organ transplantation. Am J Transplant 2006; 6: 2356.
79. Gerna G, Lilleri D, Chiesa A, et al,. Virologic and immunologic monitoring of cytomegalovirus to guide preemptive therapy in solid-organ transplantation. Am J Transplant 2011; 11: 2463.
80. Lilleri D, Zelini P, Fornara C, Comolli G, Gerna G,. Inconsistent responses of cytomegalovirus-specific T cells to pp65 and IE-1 versus infected dendritic cells in organ transplant recipients. Am J Transplant 2007; 7: 1997.
81. + T cells informs the risk of CMV replication after transplantation. Am J Transplant 2013; 13: 738.
82. Bestard O, Lucia M, Crespo E, et al,. Pretransplant immediately early-1-specific T cell responses provide protection for CMV infection after kidney transplantation. Am J Transplant 2013; 13: 1793.
83. La Rosa C, Limaye AP, Krishnan A, Longmate J, Diamond DJ,. Longitudinal assessment of cytomegalovirus (CMV)-specific immune responses in liver transplant recipients at high risk for late CMV disease. J Infect Dis 2007; 195: 633.
84. Kumar D, Chernenko S, Moussa G, et al,. Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. Am J Transplant 2009; 9: 1214.
85. + T-cell responses and T-bet levels predict immune control during early chronic infection in lung transplant recipients. J Infect Dis 2011; 204: 1663.
86. Manuel O, Husain S, Kumar D, et al,. Assessment of cytomegalovirus- specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study. Clin Infect Dis 2013; 56: 817.
87. Abate D, Saldan A, Fiscon M, et al,. Evaluation of cytomegalovirus (CMV)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis, or preemptive therapy but not antithymocyte globulin treatment contribute to CMV-specific T cell reconstitution in kidney tra. J Infect Dis 2010; 202: 585.
88. Abate D, Fiscon M, Saldan A, et al,. Human cytomegalovirus-specific T-cell immune reconstitution in preemptively treated heart transplant recipients identifies subjects at critical risk for infection. J Clin Microbiol 2012; 50: 1974.
89. Chiereghin A, Gabrielli L, Zanfi C, et al,. Monitoring cytomegalovirus T-cell immunity in small bowel/multivisceral transplant recipients. Transplant Proc 2010; 42: 69.
90. Lochmanova A, Lochman I, Tomaskova H, et al,. Quantiferon-CMV test in prediction of cytomegalovirus infection after kidney transplantation. Transplant Proc 2010; 42: 3574.
91. Egli A, Binet I, Binggeli S, et al,. Cytomegalovirus-specific T-cell responses and viral replication in kidney transplant recipients. J Transl Med 2008; 6: 29.
92. + T cells in kidney allograft recipients at risk of CMV infection. Transpl Int 2010; 23: 506.
93. Quinnan GV, Kirmani N, Rook AH, et al,. Cytotoxic T cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients. N Engl J Med 1982; 307: 7.
94. Sester M, Sester U, Gärtner BC, Girndt M, Meyerhans A, Köhler H,. Dominance of virus-specific CD8 T cells in human primary cytomegalovirus infection. J Am Soc Nephrol 2002; 13: 2577.
95. Mattes FM, Vargas A, Kopycinski J, et al,. Functional impairment of cytomegalovirus specific CD8 T cells predicts high-level replication after renal transplantation. Am J Transplant 2008; 8: 990.
96. Lisboa LF, Kumar D, Wilson LE, Humar A,. Clinical utility of cytomegalovirus cell-mediated immunity in transplant recipients with cytomegalovirus viremia. Transplantation 2012; 93: 195.
97. Radha R, Jordan S, Puliyanda D, et al,. Cellular immune responses to cytomegalovirus in renal transplant recipients. Am J Transplant 2005; 5: 110.